BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
ZUG, Switzerland, March 8, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 29th Annual Roth Conference on Tuesday, March 14, 2017, at 12:30 pm Pacific Time. A live webcast of the event will be available through the Events and Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
